Lilly Focuses On Ruboxistaurin Retinopathy NDA After Failed Neuropathy Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
Two trials of reboxistaurin (proposed trade name Arxxant) in diabetic peripheral neuropathy fail to demonstrate statistically significant differences in sensory symptom scores.